| Name | Title | Contact Details |
|---|
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as SoftVue™, three critical sound characteristics are measured and refined through proprietary algorithms, advancing this technology far beyond traditional b-mode ultrasound. By collecting and defining reflection, sound speed, and attenuation data in a 360° orientation, data are gathered and reconstructed in tomographic coronal planes, providing an enriched image set presented for cross-sectional review. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Delphinus was formed in 2010 as a spin-out of Karmanos Cancer Institute [KCI] in Detroit, MI. Created by Peter Littrup, MD of Karmanos and Neb Duric, PhD of Wayne State University Detroit, MI the SoftVue technology presents a new imaging paradigm in breast disease assessment. Karmanos Cancer Institute has served as a primary investigational site for case collection and clinical studies. Delphinus holds numerous patents and proprietary assets for its innovative and scientifically-advanced works and is poised to usher in a new era of breast imaging.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.
It is hard to believe that 17 years ago, Jim and Kathy Coover founded Isagenix in partnership with John Anderson and six employees in a small office in Tempe, AZ. Today, we are the largest company by revenue headquartered in Gilbert, AZ, and the 4th largest for-profit company in AZ. We continue to gain recognition and respect for our strong business practices both nationally and internationally. Our honors have included the Better Business Bureau naming us a 2018 BBB Torch Awards for Ethics Finalist in recognition of our commitment to “do the right thing.” In addition, Jim Coover was named 2017 CEO of the Year, and in 2018 and 2019 we were named one of the Best Places to Work, one of the Healthiest Employers, and one of the Valley`s 10 Largest Corporate Philanthropists. Today our family-owned and operated business is in 14 markets, has half a million customers worldwide, and offers more than 100 life-changing products, packs, and systems!
Medical Business bureau is a Park Ridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
America's PPO is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.